Our Pricing

Mounjaro Reviews UK: What Are The Side Effects?

Published on: June 03, 2026

Searching for mounjaro reviews uk side effects before starting treatment? At Cured Pharmacy, our UK clinical team has supported thousands of patients through tirzepatide therapy. This evidence-based guide examines real patient experiences, clinical trial safety data, and how to manage common side effects effectively.

What UK Patients Say About Mounjaro: Real Reviews and Experiences

UK patient reviews of Mounjaro consistently highlight significant weight loss results alongside manageable gastrointestinal side effects during the initial weeks. Most patients report that nausea and digestive changes diminish substantially after the first month as the body adapts to tirzepatide [1].

In our experience at Cured Pharmacy, patients who follow the gradual dose escalation protocol experience fewer severe side effects. The structured dosing schedule—starting at 2.5mg weekly and increasing every four weeks—allows your digestive system to adjust progressively to the medication's effects [1].

Common positive experiences reported by UK patients include reduced appetite within days of the first injection, sustained energy levels despite lower calorie intake, and improved glycaemic control for those with type 2 diabetes. The once-weekly injection schedule is frequently praised for its convenience compared to daily medications like Saxenda.

Patient-Reported Effectiveness

Clinical trial data shows that 91% of participants on Mounjaro 15mg achieved at least 5% body weight reduction, with 57% achieving over 20% weight loss over 72 weeks [1]. These results align closely with real-world patient experiences reported through UK pharmacy consultations and follow-up assessments.

Mounjaro Side Effects UK: What the Clinical Evidence Shows

The most frequently reported side effects of Mounjaro in UK clinical trials are gastrointestinal in nature. Nausea affects approximately 25-30% of patients, particularly during dose escalation phases, whilst diarrhoea and constipation each affect around 20% of users [1][2].

These side effects are typically mild to moderate in severity and decrease significantly after the first 8-12 weeks of treatment. In the SURPASS clinical trial programme, only 6.2% of patients discontinued tirzepatide due to gastrointestinal adverse events, compared to 2.7% on placebo [2].

Less common but notable side effects include injection site reactions (redness, itching, or mild swelling affecting 5-8% of patients), fatigue during the initial adjustment period, and mild headaches. Serious adverse events such as pancreatitis or severe allergic reactions are rare, occurring in less than 1% of clinical trial participants [2].

Managing Mounjaro Side Effects: Practical Guidance from UK Pharmacists

To minimise nausea, our UK clinical team recommends eating smaller, more frequent meals rather than three large meals daily. Avoiding high-fat, spicy, or heavily processed foods during the first month can significantly reduce digestive discomfort. Many patients find that ginger tea or plain crackers help settle the stomach if nausea occurs.

Staying well-hydrated is essential, particularly if you experience diarrhoea or reduced appetite. Aim for at least 2 litres of water daily, and consider oral rehydration solutions if digestive symptoms are pronounced. Constipation can often be managed through increased fibre intake from vegetables, fruits, and whole grains, alongside adequate fluid consumption.

If side effects become troublesome, contact your prescriber before your next scheduled dose increase. They may recommend maintaining your current dose for an additional four weeks to allow better tolerance, or provide specific medications to manage symptoms whilst your body adjusts to tirzepatide.

When to Seek Medical Advice

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of thyroid tumours (lump in the neck, difficulty swallowing, persistent hoarseness). These serious side effects are rare but require prompt clinical assessment [2][3].

Mounjaro Safety Profile: MHRA Licensing and Long-Term Data

Mounjaro received UK MHRA approval in September 2023 following extensive evaluation of safety data from over 6,000 participants across the SURPASS clinical trial programme [2]. The medication is licensed specifically for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities.

Long-term safety data spanning up to 72 weeks demonstrates that tirzepatide maintains a consistent safety profile throughout extended treatment. Cardiovascular safety analyses showed no increased risk of major adverse cardiac events, and some secondary endpoints suggested potential cardiovascular benefits [3].

The MHRA mandates specific prescribing precautions for Mounjaro. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia syndrome type 2, and during pregnancy or breastfeeding. Your UK prescriber will assess these factors during your clinical consultation before prescribing.

Mounjaro vs Wegovy Side Effects: Comparing GLP-1 Medications

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to the GLP-1 receptor agonist class and share similar side effect profiles, predominantly gastrointestinal symptoms. However, tirzepatide's dual GIP/GLP-1 mechanism may produce slightly different tolerability patterns in some patients [1][4].

Comparative trial data suggests that nausea rates are broadly similar between the two medications—approximately 25-30% for both—though individual patient responses vary considerably. Some patients who experience persistent side effects on semaglutide report better tolerance when switching to tirzepatide, whilst others find the opposite [4].

The key difference lies in efficacy rather than safety: Mounjaro demonstrated superior weight loss outcomes in head-to-head comparisons, with average reductions of 22.5% versus 15.8% for semaglutide at comparable treatment durations [1][4]. This enhanced effectiveness may justify persisting through initial side effects for many patients, subject to prescriber guidance.

Choosing Between Mounjaro and Wegovy

Your UK prescriber will consider your medical history, previous medication responses, weight loss goals, and budget when recommending between tirzepatide and semaglutide. At Cured Pharmacy, Mounjaro is available from £124.99, with transparent pricing shown before your clinical consultation. Both medications require the same once-weekly injection schedule and similar lifestyle modifications for optimal results.

Starting Mounjaro Safely: What to Expect During Your First Month

All patients begin Mounjaro at the 2.5mg starter dose, administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm. This low initial dose minimises side effects whilst allowing your body to adapt to tirzepatide's metabolic effects. You'll maintain this dose for four weeks before increasing to 5mg [1].

During the first fortnight, expect reduced appetite and possible mild nausea, particularly 1-3 days after each injection when tirzepatide levels peak. Most patients notice decreased food cravings and earlier satiety when eating. Weight loss typically begins within the first two weeks, averaging 2-4% of body weight by week four in clinical trials [1].

Keep a symptom diary during your first month, noting any side effects, their severity, and what helps manage them. This information is valuable for your prescriber when assessing whether to proceed with dose escalation. At Cured Pharmacy, our UK clinical team provides ongoing support throughout your treatment journey, with follow-up consultations available as needed.

Preparing for Your First Injection

Before starting Mounjaro, ensure you understand proper injection technique through the patient information leaflet or online tutorial videos. Store your KwikPen in the refrigerator between 2-8°C, and allow it to reach room temperature 30 minutes before injection to reduce injection site discomfort. Rotate injection sites weekly to prevent lipohypertrophy (thickened fatty tissue) at injection areas.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Dahl, D., et al. (2022). Safety and tolerability of tirzepatide in patients with type 2 diabetes: A pooled analysis of the SURPASS clinical programme. Diabetes, Obesity and Metabolism, 24(10), 1950–1961. https://doi.org/10.1111/dom.14772 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): Summary of Product Characteristics. UK Public Assessment Report. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine licensed by the MHRA for weight management in adults meeting specific clinical criteria, subject to prescriber approval.